Martek/Abbott exclusive supply deal
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences will serve as exclusive worldwide supplier of DHA and ARA for Abbott Nutrition's infant formula products, including Similac Advance, under a new, long-term supply agreement announced Oct. 8. Abbott signed a 25-year, non-exclusive supply agreement with Martek in 2000 that will remain in effect (1"The Tan Sheet" Sept. 29, 2003, p. 14). The new deal provides for a 10-year term, though Abbott can terminate as of January 2012. Martek's life'sDHA and life'sARA ingredients are used in more than 95% of U.S. infant formulas...
You may also be interested in...
Martek Pursues Cheaper DHA Cost Structure To Give Ingredient Wider Appeal
Martek Biosciences is working toward substantially lowering the cost of making docosahexaenoic acid (DHA) through a business venture with a genetics seed company
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.